289 results on '"Holweg, Cecile"'
Search Results
2. A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk
3. Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma
4. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma
5. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA
6. Response to Omalizumab in Black and White Patients with Allergic Asthma
7. Omalizumab response in patients with asthma by number and type of allergen
8. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities
9. Racial/ethnic differences in eligibility for asthma biologics among pediatric populations
10. Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
11. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma
12. Combined Assessment of Serum Periostin and YKL-40 May Identify Asthma-COPD Overlap
13. Urinary eicosanoids - novel biomarkers in T2-low severe asthma
14. Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma
15. U-BIOPRED: evaluation of the value of a public–private partnership to industry
16. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids
17. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma
18. Similar response to omalizumab in children with allergic asthma from different racial backgrounds
19. Sputum periostin is a biomarker of type 2 inflammation but not airway dysfunction in asthma
20. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
21. Improvements In The Respiratory-Related Patient-Reported Outcomes AQLQ and miniRQLQ Are Similar Across Different Omalizumab Dosing Regimens
22. Age of asthma onset does not impact the response to omalizumab
23. Serum periostin levels in adults of Chinese descent: an observational study
24. A genome-wide association study of chronic spontaneous urticaria risk and heterogeneity
25. Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes
26. Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study
27. Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility
28. Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population
29. Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development
30. A genome-wide association study of chronic spontaneous urticaria risk and heterogeneity.
31. Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps
32. A Comprehensive Analysis of the Stability of Blood Eosinophil Levels
33. The role of periostin in tissue remodeling across health and disease
34. Roles of Periostin in Respiratory Disorders
35. Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
36. Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma
37. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
38. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma
39. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis
40. Urinary Leukotriene E-4 and Prostaglandin D-2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation A Clinical Observational Study
41. The Impact of Omalizumab Therapy on Sleep in Patients With Nasal Polyps
42. Pregnancy and infant outcomes among pregnant women with Chronic Spontaneous Urticaria (CSU) treated with omalizumab: a descriptive analysis from the EXPECT pregnancy registry
43. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate‐to‐severe asthma
44. Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
45. RESPONSE TO OMALIZUMAB TREATMENT IN PATIENTS WITH FIXED AIRFLOW OBSTRUCTION
46. Inflammation and Autoantibody Markers Identify Rheumatoid Arthritis Patients With Enhanced Clinical Benefit Following Rituximab Treatment
47. Changes in gene expression in synovial tissue from refractory rheumatoid arthritis patients treated with rituximab
48. Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatability
49. Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis
50. Response to omalizumab in allergic asthma patients from different racial backgrounds
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.